Loading clinical trials...
Loading clinical trials...
The aim of the study is to define preferential sites of tumour recurrence by observing tracer uptake in the tumour in sequential PET images with 18F-fluoromethylcholine (and perfusion MR, see also below). Changes in the intensity of the tracer uptake in the tumour during and after the course of radiotherapy will be correlated with the site of tumour recurrence as will be assessed by conventional MRI. In due time, these results must enable clinicians to change their therapeutic approach of high-grade glioma.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University Hospital Ghent
Ghent, Belgium
Start Date
January 12, 2010
Primary Completion Date
March 14, 2017
Completion Date
March 22, 2018
Last Updated
May 18, 2018
90
ACTUAL participants
PET images with 18F-fluoromethylcholine
RADIATION
Lead Sponsor
University Ghent
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions